AZD2171: A Highly Potent, Orally Bioavailable, Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor for the Treatment of CancerStephen R. Wedge, Donald Ogilvie|Cancer Research|2005Cited by 710
The Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) Enhances the Radiation Responsiveness of Lung and Colorectal Tumor XenograftsAoife M. Shannon, Stephen R. Wedge|Clinical Cancer Research|2009Cited by 51
Simultaneous targeting of glycolysis and oxidative phosphorylation as a therapeutic strategy to treat diffuse large B-cell lymphomaRichard A. Noble, Stephen R. Wedge|British Journal of Cancer|2022Cited by 48